Gwangseong Kim, PhD
Principal Scientist at VitaKey Inc.- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
-
English Full professional proficiency
-
Korean Native or bilingual proficiency
Topline Score
Bio
Experience
-
VitaKey Inc.
-
United States
-
Biotechnology
-
1 - 100 Employee
-
Principal Scientist
-
Mar 2022 - Present
Head of the Cambridge team R&D, Analytical, Toll manufacturing, CRO handling Leading the development and launch of oral delivery products for nutriceuticals Natural materials-based lipid formulation development Project management Team management, team building, hiring Head of the Cambridge team R&D, Analytical, Toll manufacturing, CRO handling Leading the development and launch of oral delivery products for nutriceuticals Natural materials-based lipid formulation development Project management Team management, team building, hiring
-
-
-
-
Principal Scientist
-
May 2020 - Present
Pre-clinical and clinical bioanalytical method development and validation with GLP compliance Leading DM/PK analysis for oncology drugs and infectious disease drugs Inventor/developer of nanoliposomal formulation for COVID related Acute Respiratory Distress Syndrome (ARDS) (LEAF-4L6715, https://clinicaltrials.gov/ct2/show/NCT04378920) Specialty: LC-MS/MS based bioanalytical method development and validation. Separation to determine Encapsulated drug vs Released free drug vs Total drug… Show more Pre-clinical and clinical bioanalytical method development and validation with GLP compliance Leading DM/PK analysis for oncology drugs and infectious disease drugs Inventor/developer of nanoliposomal formulation for COVID related Acute Respiratory Distress Syndrome (ARDS) (LEAF-4L6715, https://clinicaltrials.gov/ct2/show/NCT04378920) Specialty: LC-MS/MS based bioanalytical method development and validation. Separation to determine Encapsulated drug vs Released free drug vs Total drug in vivo
-
-
Senior Scientist
-
Aug 2018 - Apr 2020
Leading formulation development for oncology and infectious diseases Leading Bioanalytical method development and validation with GLP compliance Leading biodistribution studies in animal model using LC-MS/MS Leading drug metabolization studies
-
-
Formulation Scientist
-
Aug 2017 - Jul 2018
Pre-clinical R&D for formulation development in oncology and sepsis (nano-liposome) Specialty in active loading and modified passive loading to maximum drug loading efficiency
-
-
-
Icahn School of Medicine at Mt Sinai
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Chief Technology Officer (CTO)
-
Jul 2015 - Jun 2017
Serve as the Senior Research Scientist orchestrating and conducting R&D for a variety of products and projects, including R&D for an immuno-capturing method for circulating tumor cells (CTC’s) and infectious pathogens. Conduct R&D for targeted therapy using antibody-drug conjugates for CTC’s and infectious bacteria. Provide critical technical support to ensure effective and timely filing of patents and grant submissions. • Established an in vivo rat sepsis model and performed in vivo… Show more Serve as the Senior Research Scientist orchestrating and conducting R&D for a variety of products and projects, including R&D for an immuno-capturing method for circulating tumor cells (CTC’s) and infectious pathogens. Conduct R&D for targeted therapy using antibody-drug conjugates for CTC’s and infectious bacteria. Provide critical technical support to ensure effective and timely filing of patents and grant submissions. • Established an in vivo rat sepsis model and performed in vivo investigations. • Secured Nondisclosure Agreements with BioRad, BioMerieux, and Neogen. • Developed an antibody drug conjugate and antibody conjugated substrates while independently conducting required bench works.
-
-
Sr. Research Scientist
-
Apr 2014 - Jun 2015
R&D for immunocapturing for circulating tumor cells (CTCs), photoimmunotherapy for CTCs, drug-antibody conjugation development, inductive heating based therapy for atherosclerosis
-
-
-
-
Interim Chief Technology Officer
-
Aug 2013 - Apr 2014
Launched University of Michigan start-up company, as a co-founder, for proprietary two-beads cell isolation and sorting methods. Provided technical leadership for business development and interviewed 103 industrial executives, vice presidents of R&D, directors, and academic leaders in biologics. Launched University of Michigan start-up company, as a co-founder, for proprietary two-beads cell isolation and sorting methods. Provided technical leadership for business development and interviewed 103 industrial executives, vice presidents of R&D, directors, and academic leaders in biologics.
-
-
-
University of Michigan
-
United States
-
Higher Education
-
700 & Above Employee
-
Team Leader University of Michigan - DOW Chemical co-development project
-
Jan 2012 - Jul 2013
Directed and lead the co-op project in the development of intra nasal drug delivery formulation using DOW cellulosic polymers. Gained invaluable experience in nasal physiology and formulation parameters for nasal drug delivery, including excipients, epithelial, permeability, and bioavailability. • Discovered induced thermogelation at body temperature by polymeric excipients. • Developed synthetic high-density lipoprotein (HDL) nanoparticles and lipid nanoparticles for drug delivery… Show more Directed and lead the co-op project in the development of intra nasal drug delivery formulation using DOW cellulosic polymers. Gained invaluable experience in nasal physiology and formulation parameters for nasal drug delivery, including excipients, epithelial, permeability, and bioavailability. • Discovered induced thermogelation at body temperature by polymeric excipients. • Developed synthetic high-density lipoprotein (HDL) nanoparticles and lipid nanoparticles for drug delivery applications.
-
-
Post-doc research fellow in the Department of Chemistry
-
May 2008 - Dec 2011
Conducted research on nanomedicine and nanoparticle based bioanalytics and on targeted drug delivery to brain cancers, breast cancers, and heart diseases. Advanced expertise in cytotoxicity, cell viability, endocytosis, antibody-antigen affinity, and oxidative stress. • Developed conjugation chemistry for peptide, protein, antibody, nucleotides, and sugars. • Researched therapies, diagnostics, bio sensing, and biomedical imaging.
-
-
Education
-
University of Michigan
Doctor of Philosophy (PhD), Biomedical Engineering -
University of Michigan, Ann Arbor
Master’s Degree, Biomedical Engineering -
Hanyang University
Bachelor’s Degree, Chemical Engineering